Вакансия из Hirify Global, списка международных tech-компаний Для мэтча и отклика нужен Plus
Пожаловаться
Зарплата и рынок
развернуть
$191к-300к/год
$180к$220кмедиана$250к
По похожим ролям (50) ~ $220к/год
91
Крутая вакансия
развернуть
Чётко очерченная руководящая научная роль в крупной биофармацевтической компании: она предполагает влияние на решения разных команд и работу с программами на всех этапах клинической разработки.
Понятная зона ответственности
Влияние на разработку
Онкологические исследования
?Гибридный формат
Мэтч & Сопровод
Для мэтча с этой вакансией нужен Plus
Подключить Plus
Описание вакансии
Текст:
Hirify AI/Оригинал
TL;DR
Principal Scientist (Translational Clinical Biomarkers - Hematology/Oncology) (CML/BCR::ABL1): Developing and leading translational and clinical biomarker strategies for hematology programs across clinical development with an accent on molecular disease biology, treatment response, resistance mechanisms, and patient selection. Focus on integrating NGS, PCR, MRD, flow cytometry, pharmacology, and longitudinal clinical data to guide dose optimization, registrational strategy, and go/no-go decisions.
Location: Hybrid; primary location in North Wales, Pennsylvania, USA. The posting is for US and Puerto Rico residents only. Domestic relocation is listed.
Salary: $190,800–$300,300 annual base salary for the primary location; annual bonus and long-term incentive may apply.
Company
hirify.global is a biopharmaceutical company developing medicines and advancing clinical research across oncology and other therapeutic areas.
What you will do
Develop and lead integrated translational and clinical biomarker strategies for hematology programs, especially CML, BCR::ABL1-driven disease, and other myeloid malignancies.
Translate disease biology, therapeutic mechanisms, molecular heterogeneity, clonal evolution, treatment response, and resistance into actionable biomarker plans.
Define biomarkers supporting proof of biology, target engagement, dose and regimen selection, patient selection, molecular response, resistance characterization, and go/no-go decisions.
Integrate molecular response and MRD assessments, mutation profiling, clinical outcomes, treatment history, preclinical pharmacology, and longitudinal clinical data.
Lead interpretation of complex biomarker and clinical datasets and provide strategic recommendations to cross-functional development teams and senior stakeholders.
Partner with Discovery, Clinical Development, Quantitative Sciences, Regulatory, Data Science, Clinical Operations, Pathology, Diagnostics, and external scientific collaborators.
Requirements
Ph.D., M.D., or equivalent advanced scientific degree in hematology, oncology, molecular biology, translational medicine, pharmacology, or a related discipline.
Significant experience developing and executing translational or clinical biomarker strategies in hematology or oncology drug development.
Strong understanding of hematologic malignancies, molecular drivers, treatment response, resistance mechanisms, and clonal evolution.
Experience translating disease biology and therapeutic mechanisms into biomarker strategies that inform clinical development decisions.
Working knowledge of molecularly targeted therapies and the relationships between pharmacology, disease biology, resistance, clinical endpoints, and development strategy.
Experience interpreting molecular and cellular biomarker data using one or more of NGS, quantitative PCR, molecular response or MRD assays, flow cytometry, gene-expression profiling, or other genomic approaches.
Experience leading cross-functional scientific activities in a matrixed organization and influencing decisions without direct authority.
Strong analytical, problem-solving, communication, scientific writing, and presentation skills, including the ability to synthesize multidimensional datasets into decision-oriented conclusions.
Working knowledge of biostatistics, bioinformatics, quantitative sciences, and integrated biomarker data analysis, with a strategic focus on rigorous, scalable, actionable evidence.
Nice to have
Direct experience with CML, BCR::ABL1 biology, tyrosine kinase inhibitor development, and mechanisms of sensitivity and resistance.
Experience with other myeloid malignancies, including myeloproliferative neoplasms and acute myeloid leukemia.
Familiarity with CML molecular response monitoring, BCR::ABL1 International Scale reporting, major molecular response, deep molecular response, and treatment-response guidelines.
Experience integrating resistance profiling, pharmacology, longitudinal clinical molecular data, genomic and cellular biomarkers, and clinical outcomes.
Experience supporting targeted or emerging therapeutic modalities, late-stage or registrational programs, companion diagnostics, regulatory interactions, mentoring, or external scientific collaborations.
Culture & Benefits
Hybrid work arrangement with a regular daytime shift.
Comprehensive medical, dental, vision, insurance, retirement, and 401(k) benefits.
Paid holidays, vacation, compassionate leave, and sick days.
Collaborative and inclusive environment focused on scientific rigor, respectful challenge, and cross-functional problem-solving.
Travel requirement: 10%; visa sponsorship is not available.
Hiring process
Applications are accepted through the hirify.global careers portal; the posting is effective until the day before the stated November 13, 2026 end date.
Accommodation support is available during the hiring process for eligible US and Puerto Rico applicants.
Будьте осторожны
Если работодатель просит войти в их систему, используя iCloud/Google, прислать код/пароль, запустить код/ПО, не делайте этого. Это мошенники. Обязательно жмите «Пожаловаться» или пишите в поддержку. Подробнее в гайде →